Beta-Cell Function Monitoring Study for Type 1 Diabetes (BETA Pilot)

For individuals living with Type 1 diabetes (T1D) and their caregivers, understanding the body's remaining ability to produce insulin is a topic of profound importance. The Beta-cell Evaluation Through Data-driven Assessments, or BETA pilot study, represents a significant step forward in non-invasive research aimed at creating future tools to monitor pancreatic health. This observational study focuses on adults with T1D to test and refine methods that may one day help people with Type 2 diabetes (T2D) or prediabetes detect early declines in their natural insulin production. The core vision is to move beyond sporadic clinic visits towards continuous, real-time assessment using everyday technology, empowering individuals with actionable insights into their metabolic health from the comfort of their homes.

The study employs a hybrid approach, combining detailed, one-time clinical assessments with long-term, at-home monitoring. A total of 28 participants will visit the Buck Institute's Clinical Research Unit in Novato, California, on two occasions for a comprehensive evaluation of their pancreatic beta-cell function. This evaluation involves an Oral Glucose Tolerance Test (OGTT), a standard clinical procedure where participants drink a sugary solution, followed by blood draws to measure key markers like C-peptide (a direct indicator of insulin production), glucose, and insulin levels. This in-clinic data provides a crucial, high-quality snapshot against which the continuous at-home data can be calibrated and validated.

The at-home phase is where the study's innovative character truly shines. For a period of up to six months, participants will integrate several wearable devices into their daily lives. They will continue using their personal continuous glucose monitor (CGM), which tracks blood sugar levels every few minutes. Additionally, the study will provide them with an Oura ring, a sleek wearable known for tracking sleep and activity, and an Empatica EmbracePlus wristband, a research-grade device that can monitor physiological signals related to stress. The goal is to collect a rich, multifaceted dataset that captures not just glucose levels, but also the potential influences on them, such as sleep quality, physical activity, and stress responses.

During these six months, participants will also complete six structured 'challenges' remotely. These are designed to be simple, at-home activities that gently stress the body's systems in a controlled way, such as a standardized meal challenge or a brief stress task. By observing how the body reacts to these challenges through the lens of the wearables, researchers hope to identify subtle patterns and biomarkers that correlate with beta-cell function. This could include how quickly glucose rises after a meal or how the body recovers from a stressful event. The primary outcomes the study is measuring are feasibility metrics: retention (how many participants complete the full six months) and adherence (how consistently they use the devices and complete the tasks). This focus underscores that the pilot's main goal is to prove that this intensive, tech-driven approach is practical and acceptable for participants before scaling it up to a larger population.

For a patient or caregiver considering participation, the eligibility criteria are specific to ensure safety and the quality of the data. Participants must be adults diagnosed with T1D, have a relatively well-managed condition as indicated by a self-reported HbA1c below 8%, and live in the San Francisco Bay Area to facilitate travel to the Buck Institute. They must also own a compatible smartphone and a Dexcom CGM, and be willing to use the provided wearables. Certain health factors and medications are exclusion criteria, such as a recent history of severe hypoglycemia, use of specific diabetes medications like GLP-1 agonists or SGLT2 inhibitors (which are more common in T2D), or allergies to dairy or soy used in the challenge tests. A key requirement is a willingness to temporarily stop using medications containing acetaminophen (like Tylenol), as it can interfere with CGM accuracy.

The potential long-term impact of this research program is substantial. In the future, the methods refined in this T1D pilot could lead to the development of a digital tool—perhaps a smartphone app—that provides a real-time estimate of beta-cell function for individuals with T2D or prediabetes. This would be a revolutionary shift from reactive care to proactive health management. Imagine receiving an alert that your body's insulin-producing capacity is trending downward, prompting you and your doctor to intervene with lifestyle changes or medications much earlier than currently possible, potentially delaying the onset of full-blown diabetes or preventing its complications. This study, conducted by 4YouandMe in collaboration with leading institutions like the Buck Institute and Phenome Health, and funded by the advanced research agency ARPA-H, is a pioneering effort to make that future a reality.

The importance of research focusing on beta-cell function cannot be overstated. Beta-cells in the pancreas are the sole producers of insulin, the hormone essential for regulating blood sugar. In Type 1 diabetes, the immune system mistakenly destroys these cells, leading to a lifelong dependence on exogenous insulin. In Type 2 diabetes and prediabetes, the cells become fatigued and dysfunctional over time, often due to insulin resistance. Being able to monitor the health and function of these cells non-invasively is considered a holy grail in diabetology. It would allow for truly personalized medicine, where interventions can be tailored to an individual's unique metabolic trajectory. Current methods for assessing beta-cell function are often complex, expensive, and infrequent, typically reserved for research settings. By leveraging consumer-grade wearables and smartphones, studies like BETA aim to democratize this critical health metric, making continuous metabolic health monitoring as accessible as checking your step count or heart rate. This pilot study is a critical first step in validating a new paradigm for understanding and managing diabetes, offering hope for more empowered and preventative healthcare for millions of people at risk for or living with diabetes.